KRAS and breast cancer: High estrogen-responsive BC is associated with Myc targets, metabolic signaling pathways, and mTORC1 signaling transduction gene sets, while low estrogen responsiveness is associated with KRAS signaling transduction.[42] KRAS signaling refers to the intracellular signaling pathways activated by the KRAS protein, a member of the RAS family of small GTPases.